Telix reported progress across its radiopharmaceutical pipeline, including Phase 3 TLX591-Tx advancement, ongoing pivotal studies, regulatory submissions, and reaffirmed FY 2026 revenue guidance of $950M–$970M.
Written By: Pharmacally Medical News Desk
Telix Pharmaceuticals reported continued progress across its therapeutic and precision medicine pipeline, alongside reaffirmed financial guidance for 2026, highlighting multiple clinical, regulatory, and commercial milestones expected over the coming year.
The company said growth in its Precision Medicine business accelerated in the first quarter of 2026, supported by increased U.S. dose volumes and expanding adoption of its PSMA imaging portfolio. Management noted that the two-product PSMA strategy and broader global commercial presence are expected to support continued growth through 2026 while advancing high-value clinical programs.
Therapeutics pipeline advances across multiple programs
Telix reported progress in its lead therapeutic candidate TLX591-Tx (lutetium-177 rosopatamab tetraxetan). Part 1 of the Phase 3 ProstACT Global trial met study objectives and demonstrated acceptable safety and tolerability, with no new safety signals observed.
The company has initiated discussions with the FDA to determine eligibility for U.S. patient participation in Part 2, a randomized treatment expansion. Enrollment for Part 2 is ongoing in Australia, New Zealand, and Canada, with site activation underway in several additional regions including China, South Korea, Japan, the United Kingdom, and others.
The company also announced that the first clinical site has opened for the pivotal LUTEON trial evaluating TLX250-Tx in advanced clear cell renal cell carcinoma, with patient recruitment underway. Initial enrollment is expected to focus outside the United States.
For TLX101-Tx (iodofalan I-131), the first patient has been enrolled in the IPAX-BrIGHT pivotal study in recurrent glioblastoma. The trial is currently open in Australia, Austria, and the Netherlands, and has received regulatory approval to begin in Belgium.
Telix continues dosing patients in the Phase 1 SOLACE study evaluating TLX090-Tx for treatment of pain associated with osteoblastic bone metastases. Additional U.S. sites were added during the quarter to accelerate recruitment.
The company also reported that interim data from the OPTIMAL-PSMA study of next-generation candidate TLX597-Tx are planned for presentation at the International Prostate Cancer Symposium in April 2026.
Precision medicine and regulatory milestones
Telix stated that its PSMA imaging portfolio continues to expand globally, with Illuccix now launched in 21 countries. The company said this growing footprint is intended to support future therapeutic launches.
Regulatory progress was also reported across imaging assets. A broad proposed label for TLX591-Px (Illuccix) is under review in China. Telix has resubmitted its U.S. NDA for TLX101-Px with additional clinical data and has submitted a marketing authorization application in Europe.
For Zircaix (TLX250-Px), Telix said it has aligned with the FDA on key requirements for Biologics License Application resubmission and is completing deliverables, targeting submission in the first half of 2026.
Corporate update and financial guidance
Telix also announced that David Gill will join the board as a non-executive director effective May 11, 2026, and is expected to assume the role of chair in due course as part of board succession planning.
The company reaffirmed its full-year 2026 revenue guidance of $950 million to $970 million. Telix also maintained projected research and development spending of $200 million to $240 million, subject to ongoing commercial milestones.
Reference
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement, 07 April 2026, https://telixpharma.com/news-views/q1-2026-strong-revenue-growth-and-therapeutics-pipeline-advancement/